Abstract
This paper presents the results of a study of patients with nonalcoholic steatohepatitis, alcoholic steatohepatitis, and drug-induced liver injury with concomitant colitis and the development of biliary insufficiency that manifests as a significant decrease in the volume of bile acids and bile. In patients with liver injury and concomitant colitis, changes in intestinal microflora were marked. After a combination therapy of this pathology with phosphatidylcholine and glycyrrhizic acid, an improvement of biochemical, clinical indicators was observed, as well as a decrease in fatty degeneration and reduction of elastographic indicators of liver fibrosis. The introduction of the drug formulations phosphatidylcholine and glycyrrhizic acid in the complex of conservative treatment of liver injury with concomitant colitis helps to prevent hepatic and intestinal complications and to increase the treatment efficacy of these diseases.
References
1. Abenavoli L, Falalyeyeva T, Boccuto L, Tsyryuk O, Kobyliak N. Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease. Pharmaceuticals. 2018;11(104):10.
2. Machado MV, Cortez-Pinto H. Non-alcoholic fatty liver disease: what the clinician needs to know. World J Gastroenterol. 2014; 20:12956-80.
3. Manzhalii E, Virchenko O, Falalyeyeva T, Beregova T, Stremmel W. Treatment efficacy of a probiotic preparation for non-alcoholic steatohepatitis: A pilot trial. J Dig Dis. 2017;18(12):698-703.
4. Neuman MG, French SW, French BA, Seitz HK, Cohen LB, Mueller S, et al. Alcoholic and non-alcoholic steatohepatitis. Exp Mol Pathol. 2014;97(3):492-510.
5. Kondro M, Mykhalchyshyn G, Bodnar P, Kobyliak N, Falalyeyeva T. Metabolic profile and morpho-functional state of the liver in rats with glutamate-induced obesity. Curr Issues Pharm. Med. Sci. 2013;2(4):379-81.
6. Drapkina ОМ, Korneeva OH, Ivashkin VT. [Treatment of nonalcoholic steatohepatitis in metabolic syndrome: focus on the essential phospholipids]. Lechaschiy Vrach. 2010;2:43-5.
7. Gerok V, Blum KhE. [Liver and biliary system]. M.: МЕDpress-inform; 2009:199.
8. Bataller R, Gao B. Liver fibrosis in alcoholic liver disease. Semin Liver Dis. 2015;35:146-56.
9. Weiler S, Merz M, Kullak-Ublick GA. Drug-induced liver injury: the dawn of biomarkers? F1000 Prime Rep. 2015;7:34.
10. Polunina TE, Maev IV. [Nonalcoholic fatty liver disease: epidemiology, pathogenesis, diagnosis, treatment]. Gastroenterologiya. 2012;1. Article in Russian
11. Voieikova DO, Kondro MM, Falaleyeva TM, Ostapchenko LI. Activity of enzymes of mitochondrial electron transport chain of rat hepatocytes under different steatosis. Research Journal of Pharmaceutical, Biological and Chemical Sciences. 2016;7(4):752-5.
12. Kondro M., Kobyliak N, Virchenko O, Falalyeyeva T, Beregova T, Bodnar P. Multiprobiotic therapy from childhood prevents the development of nonalcoholic fatty liver disease in adult monosodium glutamate-induced obese rats. Curr Issues Pharm. Med. Sci. 2014;2(4):243-5.
13. Baykova IE, Nikitin IG. [Drug liver]. Ross. Med. Zhurn. 2009;1. Article in Russian
14. Buyeverov AO, Yeshanu VS, Mayevskaya MV, Ivashkin VT. [Application of essential phospholipids in complex therapy of steatohepatitis of the mixed origin]. Klin. Persp. Gastroenterol. Hepatol. 2008;1:17-22. Article in Russian
15. Weismuller TJ, Lankisch TO. [Biliary diseases – new insights and developments]. Dtsch. Med. Wochenschr. 2011;136:713.
16. Kompanets I, Korotkiy A, Karpovets T, Ostapchenko L, Pilipenko S, Yankovskiy D. The interferon production and 2',5'-oligoadenylate-synthetase activity in rat spleen lymphocytes at ypoacidity evoked by omeprazole injection and at administration of multiprobiotic «SYMBITER®». Curr Issues Pharm. Med. Sci. 2013;2(4):398-400.
17. Korotkyi O, Vovk A, Blokhina O, Dvorshchenko K, Falalyeyeva T, Abenavoli L et al. Effect of Chondroitin Sulfate on blood serum cytokine profile during Carrageenan-induced edema and Mono-iodoacetate-induced osteoarthritis in rats. Rev Recent Clin Trials. 2018;2.
18. Khomeriki SG, Khomeriki NM. [Alcoholic liver disease: pathogenesis, morphological manifestations, differential diagnosis and pathogenetic approaches to therapy]. Gastroenterologiya. 2012;1. Article in Russian
19. Velkov VV. [Non-invasive biomarkers of fibrosis. Good-bye, biopsy?] Kliniko-laboratornyy consilium. 2009:30
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
Copyright (c) 2019 Autors